Van Herk Investments B.V., along with affiliated entities and Mr. Adrianus van Herk, filed this Amendment No. 7 to Schedule 13D reporting a 10.9% beneficial ownership stake in ProQR Therapeutics N.V., representing 15,384,250 ordinary shares. The filing marks a significant escalation in shareholder activism. On July 27, 2026, the reporting persons filed a petition with the Enterprise Chamber of the Amsterdam Court of Appeal seeking an investigation into the company's policies and conduct since May 2024. The reporting persons allege systemic deviations from ProQR's governance framework, specifically citing concerns over board composition, director independence, and executive compensation that is not performance-based. A primary grievance is the reappointment of Chairman James Shannon, whose tenure exceeds the 12-year maximum prescribed by the Corporate Governance Code and the company’s own Board Rules. The petitioners request the appointment of an independent non-executive director as immediate relief to strengthen oversight. While the shares were acquired for investment purposes, the reporting persons reserve the right to pursue further legal remedies or propose changes to the board and capitalization structure to address ongoing underperformance and value destruction.